Key result
Higher PIIINP levels were significantly associated with worse health-related quality of life scores and decreased odds of achieving a walk distance ≥330 meters (OR 0.62; 95% CI 0.43-0.90).
Why the study?
The association between collagen metabolism biomarkers and health related quality of life in pulmonary arterial hypertension patients was not well understood.
Are collagen metabolism biomarkers associated with health-related quality of life in patients with pulmonary arterial hypertension?
Cross-Sectional (n=105)
Are collagen metabolism biomarkers associated with health-related quality of life in patients with pulmonary arterial hypertension?
Serum PIIINP levels correlate strongly with health-related quality of life and exercise capacity in patients with pulmonary arterial hypertension, suggesting its utility as a biomarker for disease severity.
OBJECTIVES: The goal of this study was to investigate the association between collagen metabolism biomarkers and health related quality of life (HRQoL) in PAH patients. METHODS: We prospectively enrolled 68 stable idiopathic, anorexigen-associated, and hereditary PAH subjects and 37 healthy controls. Serum samples were analyzed for N-terminal propeptide of type III procollagen (PIIINP), c-terminal telopeptide of collagen type I (CITP), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1). The Minnesota Living with Heart Failure (MLWHF), Euro QoL-5D (EQ-5D), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and Short Form (SF-36) general health survey were administered at the time of blood draw. General linear models, as well as logistic regression models were used to assess associations between variables. RESULTS: CITP, PIIINP, MMP9, and TIMP1 levels, and all HRQoL domains were significantly different between controls and PAH patients (p<0.001 for each). Interestingly, PIIINP levels were significantly associated with MLWHF physical (coef=1.63, and p=0.02), SF-36 physical (coef=-2.93, p=0.004), and EQ-5D aggregate (coef=0.34, p=0.001) scores. Several of the CAMPHOR scores strongly linearly associated with PIIINP. The odds of obtaining a walk distance ≥330 meters decrease by 38% per unit increase in PIIINP (OR=0.62; 95% CI=0.43, 0.90) and a PIIINP cutoff of 5.53 μg/L provided 81% sensitivity and 82% specificity. CONCLUSIONS: PIIINP is a good predictor of disease severity, and is strongly related to HRQoL scores in PAH patients. These relationships suggest PIIINP as a promising tool for PAH clinicians to determine or confirm the level of disease severity.
No takes yet. Share an insight, caveat, or question.
A 2015 study conducted a cross-sectional in Pulmonary Arterial Hypertension (n=105). PIIINP levels vs. Healthy controls / lower PIIINP levels was evaluated on Walk distance ≥330 meters (OR 0.62, 95% CI 0.43-0.90). Higher PIIINP levels were significantly associated with worse health-related quality of life scores and decreased odds of achieving a walk distance ≥330 meters (OR 0.62; 95% CI 0.43-0.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: